Inactive Instrument

ENTREMED Stock Nasdaq

Pharmaceuticals

End-of-day quote Nasdaq
- ^USD	-

08-14	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-13	Casi Pharmaceuticals, Inc. Announces Management Changes	CI

CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	3.15M 2.71M 2.55M 2.33M 4.35M 297M 4.36M 30.09M 11.68M 152M 11.81M 11.55M 491M	P/E 2024	-1.11x	P/E 2025	-0.33x
Enterprise Value	25M 21.51M 20.24M 18.49M 34.59M 2.36B 34.68M 239M 92.81M 1.21B 93.87M 91.83M 3.9B	EV / Sales 2024	1.75x	EV / Sales 2025	1.9x
Free-Float	53.62%	Yield 2024 *	-	Yield 2025	-

08-14	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-13	Casi Pharmaceuticals, Inc. Announces Management Changes	CI
06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-15	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-20	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
04-20	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03-03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03-03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

08-14	CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results	AQ
07-01	CASI Pharmaceuticals : Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Active and Chronic Active Antibody-mediated Rejection	PU

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	21/07/2025
Kun Qian DFI	Director of Finance/CFO	44	16/05/2025
Chun Hua Wang COO	Chief Operating Officer	54	01/01/2017

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	01/04/2013
Zhen Bo Su BRD	Director/Board Member	50	21/03/2023
Thomas Folinsbee BRD	Director/Board Member	59	21/03/2023

ENTREMED Stock Nasdaq

Stocks

Pharmaceuticals

Valuation : ENTREMED

Latest news : ENTREMED

Press Releases : ENTREMED

Managers and Directors : ENTREMED

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-1.11%	-2.67%	+53.88%	+104.81%	1,034B
JOHNSON & JOHNSON	-1.11%	+2.70%	+53.99%	+71.32%	671B
ABBVIE INC.	-0.95%	+0.34%	+20.36%	+75.47%	460B
ROCHE HOLDING AG	+0.14%	-1.92%	+32.47%	+37.60%	353B
NOVARTIS AG	-1.33%	+3.96%	+25.71%	+45.03%	309B
ASTRAZENECA PLC	-1.15%	+0.30%	-1.49%	+12.31%	255B
AMGEN INC.	-0.83%	+1.06%	+56.01%	+72.04%	240B
NOVO NORDISK A/S	-0.88%	+1.15%	-17.09%	-54.39%	207B
GILEAD SCIENCES, INC.	-0.15%	+3.32%	+33.48%	+100.27%	188B
Average	-0.82%	+1.27%	+28.59%	+51.60%	412.97B
Weighted average by Cap.	-0.90%	+1.04%	+36.72%	+66.20%

	2024	2025
Net sales	28.54M 24.56M 23.1M 21.11M 39.48M 2.69B 39.59M 273M 106M 1.38B 107M 105M 4.45B	20.71M 17.82M 16.77M 15.32M 28.66M 1.96B 28.73M 198M 76.89M 1B 77.78M 76.08M 3.23B
Net income	-39.26M -33.78M -31.78M -29.03M -54.31M -3.71B -54.46M -376M -146M -1.9B -147M -144M -6.13B	-48.06M -41.35M -38.91M -35.54M -66.49M -4.54B -66.67M -460M -178M -2.33B -180M -177M -7.5B
Net Debt	6.05M 5.21M 4.9M 4.47M 8.37M 571M 8.39M 57.88M 22.46M 293M 22.72M 22.22M 944M	21.85M 18.81M 17.69M 16.16M 30.24M 2.06B 30.32M 209M 81.13M 1.06B 82.06M 80.27M 3.41B